About us

To enhance the quality of life.

Committed to developing and exploring breakthrough therapies to fulfill our promise to patients, employees, and society.

Relying on the world's leading MSC stress induction technology with its own intellectual property rights, the company has induced the screening of multifunctional proteins and solved the global drug development problems caused by the diversification of triggering factors of neurological disorders, unclear target points, and poor efficacy of single target points.

company overview

Advancing the frontier of
‍stress-induced stem cell technologies
to reshape regenerative medicine
and unlock transformative solutions
for previously unmet medical needs.

Founded in 2016, Beijing Darwin Cell Biotechnology Co., Ltd. is a national high-tech enterprise, recognized as a "Specialized, Refined, Distinctive, and Innovative" SME in Beijing and a leading innovator in the field of biopharmaceuticals. The company is also among the first batch of lead units in Beijing's Sci-Tech Innovation Consortium initiative. In collaboration with Tiantan Hospital (National Center for Neurological Disorders), Darwin Cell has established the "ALS and Neuroregeneration" Translational Research Joint Laboratory.

Our core focus lies in the research and development of cell biotechnology, including stem cells, exosomes, and protein-based polymers. We are committed to tackling global medical challenges in neuroregeneration, cartilage repair, and organ regeneration.

milestons

Two Decades of Innovation in Neuro Repair Development

Founding and Initial Development (2016 - 2021)

The company was founded in Beijing in 2016. In the initial years, it focused on establishing clinical centers and research platforms. In 2017, it set up the Mayo Yihe Clinic and Zijing Medical Management Consulting Co., Ltd. The following year, it completed the process development for Aleeto®. In 2019, it administered Aleeto® to the first neurological repair patient under compassionate use and established a second laboratory at the Second Affiliated Hospital of Tsinghua University. From 2020 to 2021, it made progress in clinical studies related to COVID-19, established a protein polymer research platform based on Aleeto®, and registered new monoclonal and consortium strains under the name “Darwin Biotech.” It also founded three subsidiaries.

Expansion and Deepening Research (2022 - 2023)

In 2022, the company was recognized as a National High-Tech Enterprise, established Darwin Nuogao (Beijing) Biotechnology Co., Ltd., and initiated clinical trials for recombinant collagen scaffold materials. In 2023, it completed corporate restructuring into two business segments: Serious/Clinical Medicine and Consumer Healthcare. It also launched the ALS clinical program for Aleeto® and initiated key national R&D projects related to Aleeto®. The company received preliminary approval for the Beijing Center for Innovation in Neural Repair Industry and led the establishment of the Beijing Neural Repair Industry Collaborative Alliance.

Transformation and Diversified Collaboration (2024)

In 2024, the company co-founded the Joint Laboratory for ALS and Neural Repair with Beijing Tiantan Hospital, Capital Medical University. It launched the “Wings of Wind” Special Charity Fund and initiated clinical studies on Alzheimer’s disease. The company also collaborated with multiple institutions, including Peking University Basic Medical Sciences, Fudan University, and Bozhen Biotech, to conduct studies on various aspects related to Aleeto® and neurological conditions.

oUR TEAM

Clinical Research, Scientific Innovation, and Biopharmaceutical Development

Our team consists of experienced scientists and industry experts with an average of over 20 years in drug development and neurobiology. With diverse backgrounds in cell biology, molecular genetics, and regenerative medicine, we specialize in tackling neurodegenerative diseases. Driven by innovation and a commitment to excellence, we integrate rigorous science with clinical application to deliver cutting-edge solutions in cell biotechnology, advancing human health and driving industry progress.